Adobe Clinical Research, LLC | Tucson, AZ

Research site

(Unclaimed)

Location

2585 N. Wyatt Drive, Tucson, Arizona, United States of America

Site insights

Top conditions

Top treatments

Rencofilstat

Linaclotide

Plecanatide

AXA1125

Cilofexor

Deudomperidone

Firsocostat

TAK-062

Cenicriviroc

MK-3655

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 17 total trials

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

The main aim is to see how TAK-062 works to reduce celiac-related symptoms and improve small intestinal damage due to gluten exposure, in participant...

Active, not recruiting

Celiac Disease

Drug: TAK-062 Placebo

Dietary Supplement: Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling

Diabetic Gastroparesis

Drug: Placebo

Drug: CIN-102 Dose 2

A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis (ASCEND)

This is a randomized, double-blind, placebo-controlled, parallel-dosing, multi-center study to evaluate the efficacy and safety of Rencofilstat as ev...

Active, not recruiting

Fibrosis, Liver

Nonalcoholic Steatohepatitis (NASH)

Drug: Placebo

Drug: Rencofilstat

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) (U-ACHIEVE)

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting

Ulcerative Colitis (UC)

Drug: Placebo

Drug: Upadacitinib (ABT-494)

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (stea...

Enrolling

Non Alcoholic Steatohepatitis (NASH)

Drug: AXA1125

Drug: Placebo

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (WAYFIND)

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting

Nonalcoholic Steatohepatitis

Drug: PTM CILO/FIR

Drug: Cilofexor (CILO)/Firsocostat (FIR)